



Venetoclax

Catalog No: tcsc1155





Alternative Names:

GDC-0199;ABT-199

Observed Molecular Weight:

868.44

Product Description

 $Venetoclax (GDC-0199; ABT-199) is a highly potent, selective and orally bioavailable {\bf Bcl-2} inhibitor with a {\bf K_i} of less than 0.01 nM.$

IC50 & Target: Ki: 444 nM (Mcl-1)^[1]

In Vitro: Venetoclax (ABT-199) potently kills FL5.12-BCL-2 cells (EC $_{50}$ =4 nM), Venetoclax (ABT-199) shows much weaker activity against FL5.12-BCL-XL cells (EC $_{50}$ =261 nM). ABT-199 also shows selectivity in cellular mammalian two-hybrid assays, where it disrupts BCL-2-BIM complexes (EC $_{50}$ =3 nM) but is much less effective against BCL-XL-BCL-XS (EC $_{50}$ =2.2 μ M) or MCL-1-NOXA complexes [1].

In Vivo: After a single oral dose of 12.5 mg per kg body weight in xenografts derived from RS4;11 cells (ALL), Venetoclax (ABT-199) causes a maximal tumor growth inhibition (TGI_{max}) of 47% (P[1]. Treatment of established xenografted (a mouse xenograft model of the T-ALL cell line LOUCY) tumors with Venetoclax (ABT-199) 100 mg/kg for 4 days resulted in a significant reduction of leukemic burden (P=0.0048)^[2].

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!